West Pharmaceutical
374 hedge funds and large institutions have $8.52B invested in West Pharmaceutical in 2019 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 135 increasing their positions, 122 reducing their positions, and 42 closing their positions.
13% more capital invested
Capital invested by funds: $7.5B → $8.52B (+$1.01B)
11% more repeat investments, than reductions
Existing positions increased: 135 | Existing positions reduced: 122
2% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 42
0.05% more ownership
Funds ownership: 92.35% → 92.4% (+0.05%)
1% less funds holding
Funds holding: 379 → 374 (-5)
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
90% less call options, than puts
Call options by funds: $5.02M | Put options by funds: $49.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
+$35.9M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$28.3M |
| 3 |
WCM Investment Management
Laguna Beach,
California
|
+$20.1M |
| 4 |
AAM
AMI Asset Management
Los Angeles,
California
|
+$19.3M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$15.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$24.5M |
| 2 |
Millennium Management
New York
|
-$23.6M |
| 3 |
Goldman Sachs
New York
|
-$17.6M |
| 4 |
Neuberger Berman Group
New York
|
-$15.5M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$14M |
WST Hedge Fund Activity: Q2 2019 in Review
374 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q2 2019, worth a combined $8.52B — up 13% from $7.5B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new WST positions and 42 closed out — a net gain of 1 holder — while 135 added to existing stakes and 122 trimmed.
The largest buyer was Nuveen, opening a new position worth an estimated $35.9M. The largest seller was Deutsche Bank, cutting an estimated $24.5M.
- 374 institutional investors held West Pharmaceutical (WST) as of Q2 2019, down from 379 in Q1 2019.
- Funds reported $8.52B of West Pharmaceutical stock for Q2 2019, up 13% quarter-over-quarter.
- 43 funds opened new West Pharmaceutical positions in Q2 2019 and 42 closed out, a net change of +1 holder.
- The largest West Pharmaceutical buyer in Q2 2019 was Nuveen, an estimated $35.9M added.
- The largest West Pharmaceutical seller in Q2 2019 was Deutsche Bank, an estimated $24.5M sold.
Based on aggregated 13F filings for Q2 2019.